Regulus Therapeutics Inc’s filing revealed that its President & Head of R & D Klassen Preston acquired Company’s shares for reported $95852.0 on Jun 03 ’25. In the deal valued at $7.99 per share,12,000 shares were bought. As a result of this transaction, Klassen Preston now holds 48,055 shares worth roughly $0.4 million.
Then, Hagan Joseph P bought 50,000 shares, generating $54,260 in total proceeds. Upon buying the shares at $1.09, the Chief Executive Officer now owns 260,808 shares.
Before that, BALTIMORE DAVID bought 19,610 shares. Regulus Therapeutics Inc shares valued at $20,787 were divested by the Director at a price of $1.06 per share. As a result of the transaction, BALTIMORE DAVID now holds 22,169 shares, worth roughly $0.18 million.
Wells Fargo upgraded its Regulus Therapeutics Inc [RGLS] rating to an Overweight from a an Equal weight in a research note published on March 27, 2025; the price target was increased to $6 from $3. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early August with a ‘”an Outperform”‘ rating. Leerink Partners began covering RGLS with “an Outperform” recommendation on March 18, 2024. B. Riley FBR Inc. started covering the stock on March 28, 2018. It rated RGLS as “a Neutral”.
Price Performance Review of RGLS
On Monday, Regulus Therapeutics Inc [NASDAQ:RGLS] saw its stock jump 1.36% to $8.22. Over the last five days, the stock has lost -0.96%. Regulus Therapeutics Inc shares have risen nearly 420.25% since the year began. Nevertheless, the stocks have risen 247.57% over the past one year. While a 52-week high of $8.35 was reached on 06/09/25, a 52-week low of $0.83 was recorded on 01/29/25.
Levels Of Support And Resistance For RGLS Stock
The 24-hour chart illustrates a support level at 8.10, which if violated will result in even more drops to 7.99. On the upside, there is a resistance level at 8.31. A further resistance level may holdings at 8.40.
The most recent change occurred on January 05, 2018 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $2 price target.
